Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://mangatoon.mobi
Are you over 18 and want to see adult content?
A complete backup of https://alimapure.com
Are you over 18 and want to see adult content?
A complete backup of https://us-ignite.org
Are you over 18 and want to see adult content?
A complete backup of https://groupbuyseotools.net
Are you over 18 and want to see adult content?
A complete backup of https://hgfoundation.io
Are you over 18 and want to see adult content?
A complete backup of https://mlsli.com
Are you over 18 and want to see adult content?
A complete backup of https://reviewbestseller.com
Are you over 18 and want to see adult content?
A complete backup of https://cherkizovo.com
Are you over 18 and want to see adult content?
A complete backup of https://hutchnews.com
Are you over 18 and want to see adult content?
A complete backup of https://bulkypix.com
Are you over 18 and want to see adult content?
A complete backup of https://islaculebra.com
Are you over 18 and want to see adult content?
A complete backup of https://ros-spravka.ru
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.vavel.com/colombia/futbol-colombiano/2020/02/10/rionegro-aguilas/1013129-once-caldas-vs-rionegro-aguila
Are you over 18 and want to see adult content?
A complete backup of style.udn.com/style/story/8064/4333643
Are you over 18 and want to see adult content?
A complete backup of www.rtbf.be/sport/football/etranger/italie/detail_inter-ac-milan-le-duel-lukaku-saelemaekers-live-commente-
Are you over 18 and want to see adult content?
A complete backup of www.businesstoday.in/current/economy-politics/patparganj-election-results-aap-manish-sisodia-bjp-ravi-negi-
Are you over 18 and want to see adult content?
Text
Associate
THE DEMENTIA DISCOVERY FUND The Dementia Discovery Fund (DDF) is a £250m specialist venture capital fund that invests in, and creates, new biotech companies to deliver high impact therapeutics for age-related dementias. By making meaningful, sustained, and actively managed investments we will enable the development of therapeutics addressing one of the largest globalLYNNE HUGHES
Lynne brings over 34 years of clinical research experience to the Dementia Discovery Fund and has worked exclusively in Neurology for 22 years.. Lynne joined the DDF after being Vice President and Global Head, Medical Strategy, Neurology at IQVIA. In her 22 years at IQVIA, Lynne worked exclusively in neurology and managed global development programs both from the operational perspective as aMICHAEL BALMUTH
Michael Balmuth. Managing Partner. Michael’s career spans operating roles in healthcare technology, followed by 20-plus years of growth equity investing in healthcare, software and technology-enabled services. Michael joined SV in 2014 and is focused on digital health and healthcare technology services. Michael’s current and pastdigital
RUTH MCKERNAN
In her spare time Ruth is an award winning science writer, avid gardener and spokesperson for Women in Innovation. Academic credentials. Ruth Has a BSc in Pharmacology and Biochemistry, a PhD in neuroscience and Honorary DSc from two Universities. She was made a Commander of the British Empire for services to business and innovation in 2013 andLUCA SANTARELLI
Luca Santarelli. Chair. Dr. Santarelli is the CEO of VectivBio (Nasdaq:VECT), a clinical-stage rare disease company he founded after serving as CEO and co-founder of Therachon AG, which was acquired by Pfizer in 2019 for $810 million. Prior to Therachon, Dr. Santarelli was Venture Partner at Versant Ventures, which he joined after 12years at
GREG MADDEN
Greg Madden. Managing Partner. Greg brings over 18 years of healthcare transaction experience to SV, including deep private and public healthcare company investment experience. He joined SV in 2002 as an Analyst and later transitioned to the role of Portfolio ManagerCARL CULICCHIA
Carl Culicchia. Principal. Carl joined SV in 2016 and is focused on healthcare services and digital health investments. He sourced and led investments in Doctors of Physical Therapy, Healthify, Evidation Health and Centauri Health Solutions. Carl currently serves as a board director for Doctors of Physical Therapy and Healthify and as a boardHOUMAN ASHRAFIAN
Houman Ashrafian. Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded and serves on the board of seven SV companies; Alchemab, Catamaran Bio, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee and EMPOWERING INNOVATORS TO IMPROVE PATIENTS' LIVES SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time. PEOPLE - SV HEALTH INVESTORS Carl Harald Janson Senior Advisor Public Equities UK. Christian Jung Partner Dementia UK. Jack Kenney Associate Biotech USA. Paul LaViolette Managing Partner & COO Medtech USA. Dirk Landgraf Senior Associate Dementia USA. Megan MacDonagh Associate Medtech USA. Greg Madden Managing Partner Medtech, Healthcare Growth USA. Niyoshi PatelAssociate
THE DEMENTIA DISCOVERY FUND The Dementia Discovery Fund (DDF) is a £250m specialist venture capital fund that invests in, and creates, new biotech companies to deliver high impact therapeutics for age-related dementias. By making meaningful, sustained, and actively managed investments we will enable the development of therapeutics addressing one of the largest globalLYNNE HUGHES
Lynne brings over 34 years of clinical research experience to the Dementia Discovery Fund and has worked exclusively in Neurology for 22 years.. Lynne joined the DDF after being Vice President and Global Head, Medical Strategy, Neurology at IQVIA. In her 22 years at IQVIA, Lynne worked exclusively in neurology and managed global development programs both from the operational perspective as aMICHAEL BALMUTH
Michael Balmuth. Managing Partner. Michael’s career spans operating roles in healthcare technology, followed by 20-plus years of growth equity investing in healthcare, software and technology-enabled services. Michael joined SV in 2014 and is focused on digital health and healthcare technology services. Michael’s current and pastdigital
RUTH MCKERNAN
In her spare time Ruth is an award winning science writer, avid gardener and spokesperson for Women in Innovation. Academic credentials. Ruth Has a BSc in Pharmacology and Biochemistry, a PhD in neuroscience and Honorary DSc from two Universities. She was made a Commander of the British Empire for services to business and innovation in 2013 andLUCA SANTARELLI
Luca Santarelli. Chair. Dr. Santarelli is the CEO of VectivBio (Nasdaq:VECT), a clinical-stage rare disease company he founded after serving as CEO and co-founder of Therachon AG, which was acquired by Pfizer in 2019 for $810 million. Prior to Therachon, Dr. Santarelli was Venture Partner at Versant Ventures, which he joined after 12years at
GREG MADDEN
Greg Madden. Managing Partner. Greg brings over 18 years of healthcare transaction experience to SV, including deep private and public healthcare company investment experience. He joined SV in 2002 as an Analyst and later transitioned to the role of Portfolio ManagerCARL CULICCHIA
Carl Culicchia. Principal. Carl joined SV in 2016 and is focused on healthcare services and digital health investments. He sourced and led investments in Doctors of Physical Therapy, Healthify, Evidation Health and Centauri Health Solutions. Carl currently serves as a board director for Doctors of Physical Therapy and Healthify and as a boardHOUMAN ASHRAFIAN
Houman Ashrafian. Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded and serves on the board of seven SV companies; Alchemab, Catamaran Bio, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee and PORTFOLIO - SV HEALTH INVESTORS Portfolio. For 27 years, our strategy has been consistent – identify and invest in the most promising healthcare ventures led by remarkable and inspired management teams. HEALTHCARE GROWTH NEWS In the UK, SV Health Managers LLP (registered in England OC 308829, VAT 227 0451 34) is authorised and regulated by the Financial ConductAuthority ('FCA').
BRENT FADUSKI
Brent Faduski. Chief Financial Officer. Brent brings over 19 years of finance and accounting experience to SV. He joined SV in 2008 as Controller, and focuses on finance and accounting matters for the firm. Prior to joining SV, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible forthe
THERINI BIO SECURES $17 MILLION INVESTMENT TO ADVANCE In the UK, SV Health Managers LLP (registered in England OC 308829, VAT 227 0451 34) is authorised and regulated by the Financial ConductAuthority ('FCA').
HOUMAN ASHRAFIAN
Houman Ashrafian. Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded and serves on the board of seven SV companies; Alchemab, Catamaran Bio, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee andALEX BADAMCHI
Alex Badamchi-Zadeh. Alex joined SV in 2020 as a Senior Associate in the biotechnology investment team, to help form and fund companies with impactful medicines. Additionally, Alex is involved with ongoing fund portfolio management, due diligence of new deals, and providing strategic, BD, and operational support to existing companies in the SVPAUL LAVIOLETTE
Paul brings over 35 years of global medical technology management experience to SV. He joined SV in 2009 as a Venture Partner and in 2011 was made a Partner. Paul was promoted to Managing Partner & COO in 2014 and heads our medical device investments. Prior to SV, Paul built and ran medical device businesses for 29 years before joining SV JADE WOODS - SV HEALTH INVESTORS Jade Woods. Fund Accountant. Jade joined SV in 2019 as a Fund Accountant in the finance team. She assists with the Dementia Discovery Fund and the Impact Medicine Fund, as well as helping with the management accounts. Previously, Jade worked at Moore Stephens in the audit department for three years, whilst completing her ACA.AILSA CRAIG
Ailsa Craig. Investment Manager. Ailsa joined SV Health Investors in November 2006, as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets focused team. Previously, Ailsa worked at Baring Asset Management for two years as a research analyst, covering pharmaceutical and biotechnology stocks.DOMINIC WALSH
Dominic Walsh joined Biogen in September 2018 and is the head of the Alzheimer’s Disease & Dementia Research Unit (ADRU). He is responsible for overseeing Biogen’s research and early development efforts on AD and dementia. Dominic has worked on the molecular pathology of AD since December 1991. He has authored over 150 researcharticles and
EMPOWERING INNOVATORS TO IMPROVE PATIENTS' LIVES SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time. PEOPLE - SV HEALTH INVESTORS In the UK, SV Health Managers LLP (registered in England OC 308829, VAT 227 0451 34) is authorised and regulated by the Financial ConductAuthority ('FCA').
THE DEMENTIA DISCOVERY FUND The DDF combines a sole focus on dementia with the rigor of for-profit venture capital investing. The dementia focus enables the fund to maintain its deep domain expertise in both innovative research and clinical development, apply learnings, and repeatedly engage the scientific and industrial community to refine its investment strategyover time.
LYNNE HUGHES
Lynne brings over 34 years of clinical research experience to the Dementia Discovery Fund and has worked exclusively in Neurology for 22 years.. Lynne joined the DDF after being Vice President and Global Head, Medical Strategy, Neurology at IQVIA. In her 22 years at IQVIA, Lynne worked exclusively in neurology and managed global development programs both from the operational perspective as aHOUMAN ASHRAFIAN
Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018.He has founded and serves on the board of seven SV companies; Alchemab, Catamaran Bio, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex.MICHAEL BALMUTH
Michael’s career spans operating roles in healthcare technology, followed by 20-plus years of growth equity investing in healthcare, software and technology-enabled services.AILSA CRAIG
Ailsa joined SV Health Investors in November 2006, as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets focused team.RUTH MCKERNAN
Ruth McKernan joined SV in 2018 as a Venture Partner, is co-founder of the DDF formed companies Loqus23 and AstronauTx and supported the formation of Alchemab, an SV formed company.BRENT FADUSKI
Brent brings over 19 years of finance and accounting experience to SV. He joined SV in 2008 as Controller, and focuses on finance and accounting matters for the firm.CARL CULICCHIA
Carl joined SV in 2016 and is focused on healthcare services and digital health investments. He sourced and led investments in Doctors of Physical Therapy, Healthify, Evidation Health EMPOWERING INNOVATORS TO IMPROVE PATIENTS' LIVES SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time. PEOPLE - SV HEALTH INVESTORS In the UK, SV Health Managers LLP (registered in England OC 308829, VAT 227 0451 34) is authorised and regulated by the Financial ConductAuthority ('FCA').
THE DEMENTIA DISCOVERY FUND The DDF combines a sole focus on dementia with the rigor of for-profit venture capital investing. The dementia focus enables the fund to maintain its deep domain expertise in both innovative research and clinical development, apply learnings, and repeatedly engage the scientific and industrial community to refine its investment strategyover time.
LYNNE HUGHES
Lynne brings over 34 years of clinical research experience to the Dementia Discovery Fund and has worked exclusively in Neurology for 22 years.. Lynne joined the DDF after being Vice President and Global Head, Medical Strategy, Neurology at IQVIA. In her 22 years at IQVIA, Lynne worked exclusively in neurology and managed global development programs both from the operational perspective as aHOUMAN ASHRAFIAN
Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018.He has founded and serves on the board of seven SV companies; Alchemab, Catamaran Bio, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex.MICHAEL BALMUTH
Michael’s career spans operating roles in healthcare technology, followed by 20-plus years of growth equity investing in healthcare, software and technology-enabled services.AILSA CRAIG
Ailsa joined SV Health Investors in November 2006, as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets focused team.RUTH MCKERNAN
Ruth McKernan joined SV in 2018 as a Venture Partner, is co-founder of the DDF formed companies Loqus23 and AstronauTx and supported the formation of Alchemab, an SV formed company.BRENT FADUSKI
Brent brings over 19 years of finance and accounting experience to SV. He joined SV in 2008 as Controller, and focuses on finance and accounting matters for the firm.CARL CULICCHIA
Carl joined SV in 2016 and is focused on healthcare services and digital health investments. He sourced and led investments in Doctors of Physical Therapy, Healthify, Evidation Health PORTFOLIO - SV HEALTH INVESTORS Portfolio. For 27 years, our strategy has been consistent – identify and invest in the most promising healthcare ventures led by remarkable and inspired management teams.RUTH MCKERNAN
Ruth McKernan joined SV in 2018 as a Venture Partner, is co-founder of the DDF formed companies Loqus23 and AstronauTx and supported the formation of Alchemab, an SV formed company.AILSA CRAIG
Ailsa joined SV Health Investors in November 2006, as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets focused team.GREG MADDEN
In the UK, SV Health Managers LLP (registered in England OC 308829, VAT 227 0451 34) is authorised and regulated by the Financial ConductAuthority ('FCA').
TOM FLYNN - SV HEALTH INVESTORS Tom invests in growing health care companies, focused primarily on health care services. Tom's broad investment experience spans a wide array of outpatient provider services and outsourcing businesses thatsupport clinicians.
LAURENCE BARKER
Laurence joined SV Health as Chief Business Officer of the DDF in February 2016. DDF Portfolio Board Roles Amathus Therapeutics, AstronauTx, Autifony Therapeutics, Bicycle Therapeutics, and TheriniBio.
DOMINIC WALSH
Dominic Walsh joined Biogen in September 2018 and is the head of the Alzheimer’s Disease & Dementia Research Unit (ADRU). He is responsible for overseeing Biogen’s research and early development efforts on AD and dementia.SUSAN KOHLHAAS
Susan Kohlhaas is Director of Research at Alzheimer’s Research UK where she oversees the charity’s research strategy and programme, including strategic initiatives.STEPHEN GRIGGS
In the UK, SV Health Managers LLP (registered in England OC 308829, VAT 227 0451 34) is authorised and regulated by the Financial ConductAuthority ('FCA').
LUCY COSTA DUARTE
Lucy Costa Duarte has served as Head of Investor Relations for IBT since 2016. Prior to this, Lucy spent 13 years in Equity Capital Markets at Schroders and then Citi, specialising in IPOs and follow-on equity issuance for companies from the emerging markets of Europe, the Middle East and Africa. EMPOWERING INNOVATORS TO IMPROVE PATIENTS' LIVES SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time. PEOPLE - SV HEALTH INVESTORS Carl Harald Janson Senior Advisor Public Equities UK. Christian Jung Partner Dementia UK. Jack Kenney Associate Biotech USA. Paul LaViolette Managing Partner & COO Medtech USA. Dirk Landgraf Senior Associate Dementia USA. Megan MacDonagh Associate Medtech USA. Greg Madden Managing Partner Medtech, Healthcare Growth USA. Niyoshi PatelAssociate
SV HEALTH INVESTORS ANNOUNCES FORMATION OF THE MEDTECH 6th April 2020 in SV News. Boston, MA, April 6, 2020 --- SV Health Investors announced today that it has formed the Medtech Convergence Fund (MCF), a $90 million early-stage, medtech venture-capital fund. SV has partnered with the senior members of another Boston-based VC firm, Norwich Ventures, to create this new fund and build theportfolio.
LYNNE HUGHES
Lynne brings over 34 years of clinical research experience to the Dementia Discovery Fund and has worked exclusively in Neurology for 22 years.. Lynne joined the DDF after being Vice President and Global Head, Medical Strategy, Neurology at IQVIA. In her 22 years at IQVIA, Lynne worked exclusively in neurology and managed global development programs both from the operational perspective as aMICHAEL BALMUTH
Michael Balmuth. Managing Partner. Michael’s career spans operating roles in healthcare technology, followed by 20-plus years of growth equity investing in healthcare, software and technology-enabled services. Michael joined SV in 2014 and is focused on digital health and healthcare technology services. Michael’s current and pastdigital
RUTH MCKERNAN
In her spare time Ruth is an award winning science writer, avid gardener and spokesperson for Women in Innovation. Academic credentials. Ruth Has a BSc in Pharmacology and Biochemistry, a PhD in neuroscience and Honorary DSc from two Universities. She was made a Commander of the British Empire for services to business and innovation in 2013 andHOUMAN ASHRAFIAN
Houman Ashrafian. Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded and serves on the board of seven SV companies; Alchemab, Catamaran Bio, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee andBRENT FADUSKI
Brent Faduski. Chief Financial Officer. Brent brings over 19 years of finance and accounting experience to SV. He joined SV in 2008 as Controller, and focuses on finance and accounting matters for the firm. Prior to joining SV, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible forthe
CARL CULICCHIA
Carl Culicchia. Principal. Carl joined SV in 2016 and is focused on healthcare services and digital health investments. He sourced and led investments in Doctors of Physical Therapy, Healthify, Evidation Health and Centauri Health Solutions. Carl currently serves as a board director for Doctors of Physical Therapy and Healthify and as a boardAILSA CRAIG
Ailsa Craig. Investment Manager. Ailsa joined SV Health Investors in November 2006, as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets focused team. Previously, Ailsa worked at Baring Asset Management for two years as a research analyst, covering pharmaceutical and biotechnology stocks. EMPOWERING INNOVATORS TO IMPROVE PATIENTS' LIVES SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time. PEOPLE - SV HEALTH INVESTORS Carl Harald Janson Senior Advisor Public Equities UK. Christian Jung Partner Dementia UK. Jack Kenney Associate Biotech USA. Paul LaViolette Managing Partner & COO Medtech USA. Dirk Landgraf Senior Associate Dementia USA. Megan MacDonagh Associate Medtech USA. Greg Madden Managing Partner Medtech, Healthcare Growth USA. Niyoshi PatelAssociate
SV HEALTH INVESTORS ANNOUNCES FORMATION OF THE MEDTECH 6th April 2020 in SV News. Boston, MA, April 6, 2020 --- SV Health Investors announced today that it has formed the Medtech Convergence Fund (MCF), a $90 million early-stage, medtech venture-capital fund. SV has partnered with the senior members of another Boston-based VC firm, Norwich Ventures, to create this new fund and build theportfolio.
LYNNE HUGHES
Lynne brings over 34 years of clinical research experience to the Dementia Discovery Fund and has worked exclusively in Neurology for 22 years.. Lynne joined the DDF after being Vice President and Global Head, Medical Strategy, Neurology at IQVIA. In her 22 years at IQVIA, Lynne worked exclusively in neurology and managed global development programs both from the operational perspective as aMICHAEL BALMUTH
Michael Balmuth. Managing Partner. Michael’s career spans operating roles in healthcare technology, followed by 20-plus years of growth equity investing in healthcare, software and technology-enabled services. Michael joined SV in 2014 and is focused on digital health and healthcare technology services. Michael’s current and pastdigital
RUTH MCKERNAN
In her spare time Ruth is an award winning science writer, avid gardener and spokesperson for Women in Innovation. Academic credentials. Ruth Has a BSc in Pharmacology and Biochemistry, a PhD in neuroscience and Honorary DSc from two Universities. She was made a Commander of the British Empire for services to business and innovation in 2013 andHOUMAN ASHRAFIAN
Houman Ashrafian. Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded and serves on the board of seven SV companies; Alchemab, Catamaran Bio, Enara Bio, Mestag, Sitryx, TrexBio and Zarodex. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee andBRENT FADUSKI
Brent Faduski. Chief Financial Officer. Brent brings over 19 years of finance and accounting experience to SV. He joined SV in 2008 as Controller, and focuses on finance and accounting matters for the firm. Prior to joining SV, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible forthe
CARL CULICCHIA
Carl Culicchia. Principal. Carl joined SV in 2016 and is focused on healthcare services and digital health investments. He sourced and led investments in Doctors of Physical Therapy, Healthify, Evidation Health and Centauri Health Solutions. Carl currently serves as a board director for Doctors of Physical Therapy and Healthify and as a boardAILSA CRAIG
Ailsa Craig. Investment Manager. Ailsa joined SV Health Investors in November 2006, as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets focused team. Previously, Ailsa worked at Baring Asset Management for two years as a research analyst, covering pharmaceutical and biotechnology stocks. PORTFOLIO - SV HEALTH INVESTORS Portfolio. For 27 years, our strategy has been consistent – identify and invest in the most promising healthcare ventures led by remarkable and inspired management teams.RUTH MCKERNAN
In her spare time Ruth is an award winning science writer, avid gardener and spokesperson for Women in Innovation. Academic credentials. Ruth Has a BSc in Pharmacology and Biochemistry, a PhD in neuroscience and Honorary DSc from two Universities. She was made a Commander of the British Empire for services to business and innovation in 2013 andAILSA CRAIG
Ailsa Craig. Investment Manager. Ailsa joined SV Health Investors in November 2006, as IBT Investment Analyst and became an Investment Manager in 2008, where she is part of the public markets focused team. Previously, Ailsa worked at Baring Asset Management for two years as a research analyst, covering pharmaceutical and biotechnology stocks. RAY JUPP - SV HEALTH INVESTORS Ray Jupp is a Venture Partner at SV and CSO of Mestag, an SV portfolio company.He joined the SV Venture Partner Program in September 2020.. Prior to joining SV as a Venture Partner, Ray was the founding CSO of TrexBio, an SV portfolio company focused on tissue Tregs before joining Enara Bio as CSO in late 2018 as CSO and Mestag in late 2020.JOANNA WOLAK
Joanna Wolak. Joanna brings more than 20 years of scientific experience including over 13 years of drug discovery expertise within the pharmaceutical industry to the Dementia Discovery Fund UK team. She joined the London SV group in April 2020 as Senior Advisor within the DDF Investment Team supporting the management of currentinvestments and
TOM FLYNN - SV HEALTH INVESTORS Before joining SV, Tom was a partner at Ferrer Freeman & Co., a healthcare-focused growth capital investor. From 1996 to 2010, Tom has served on numerous boards, including Aerocare Holdings, Amerita, Inc., GeneraMedix, Genova Diagnostics, PHNS, as well as Physicians Dialysis and Vitalize Consulting Solutions, both co-investments with SV.STEPHEN GRIGGS
In the UK, SV Health Managers LLP (registered in England OC 308829, VAT 227 0451 34) is authorised and regulated by the Financial ConductAuthority ('FCA').
DOMINIC WALSH
Dominic Walsh joined Biogen in September 2018 and is the head of the Alzheimer’s Disease & Dementia Research Unit (ADRU). He is responsible for overseeing Biogen’s research and early development efforts on AD and dementia. Dominic has worked on the molecular pathology of AD since December 1991. He has authored over 150 researcharticles and
SUSAN KOHLHAAS
Susan Kohlhaas. Susan Kohlhaas is Director of Research at Alzheimer’s Research UK where she oversees the charity’s research strategy and programme, including strategic initiatives. She has a PhD in cancer biology from the University of Leicester and completed postdoctoral work in the field of immunology at the Babraham Institutein Cambridge.
LUCY COSTA DUARTE
Lucy Costa Duarte has served as Head of Investor Relations for IBT since 2016. Prior to this, Lucy spent 13 years in Equity Capital Markets at Schroders and then Citi, specialising in IPOs and follow-on equity issuance for companies from the emerging markets of Europe, the Middle East and Africa.* Strategy
* Biotech
* Dementia
* Healthcare Growth
* Medtech
* Public Equities
* People
* Portfolio
* News
* Contact
*
* Investors
* Dementia Discovery Fund * Impact Medicine Fund* Growth Fund
* SV Life Sciences Funds 3-6 INVESTING IN TOMORROW’S HEALTHCARE BREAKTHROUGHS Biotech • Dementia • Healthcare Growth• Medtech
• Public Equities
*
BIOTECH
Seeking breakthroughs that have the power to change the lives ofmillions
*
DEMENTIA
Investing in innovative therapeutics for dementia*
HEALTHCARE GROWTH
Growth capital and liquidity for industry leaders transforminghealthcare
*
MEDTECH
Compelling teams and technologies with the power to changemedicine
*
PUBLIC EQUITIES
Actively managing a diversified biopharma portfolio to deliver premier risk-adjusted returns OUR GOAL IS TO TRANSFORM HEALTHCARE ONE INVESTMENT AT A TIME. By supporting the entrepreneurs who create and build breakthrough companies and treatments. Discover our Portfolio*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
WE EMPOWER INNOVATORS TO IMPROVE PATIENTS’ LIVES. And we have the track record to prove it.*
$3Bin historical commitments Global private equity and venture capital investment platform. Specialized and diversified healthcare funds spanning all sectors and stages. Five teams focused on biotechnology, dementia, healthcare growth equity, medtech and public equities.View our Strategies
*
75IPOs/M&As
Backing inspiring and talented innovators to create healthcare industry leaders that attract strategic acquirers and public investors. Our portfolio companies’ remarkable work benefits patients while growing shareholder value for investors.View our Portfolio
*
27YRStrack record in US and UK One of the longest-tenured healthcare investment managers in the world. Experienced team of >55 investment professionals and operating partners based in Boston and London, adding value and guiding strategic direction.Meet our People
OUR PEOPLE
SV is driven by our talented team and network. We bring together our experienced investment professionals with healthcare industry veterans to build value in breakthrough life sciences companies.Meet our People
THE LATEST FROM SV
We're proud to share our achievements and those of our portfoliocompanies.
*
2 June 2021Portfolio NewsTransine Therapeutics Closes Extended Seed Funding of £9.1 million co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund to advance its novel class of therapeutic RNAs*
27 May 2021Portfolio NewsPulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945*
26 May 2021Portfolio NewsQurAlis Boosts World-Class Leadership Team With Addition of Three New MembersView all News
*
STRATEGIES
* Biotech
* Dementia
* Healthcare Growth
* Medtech
* Public Equities
*
FUNDS
* Dementia Discovery Fund* Growth Fund
* Impact Medicine Fund * International Biotechnology Trust plc * Medtech Convergence Fund * View all our Funds*
USA
* One Boston Place
201 Washington StreetSuite 3900
Boston
MA 02108
USA
* +1 617 367 8100
*
UK
* 71 Kingsway
London
WC2B 6ST
UK
* +44 20 7421 7070
Privacy Policy Terms of Use The UK Stewardship Code Statement of CommitmentAnnual
‘RTS 28’ Best Execution DisclosureSV
Health Managers LLP Engagement Policy In the UK, SV Health Managers LLP (registered in England OC 308829, VAT 227 0451 34) is authorised and regulated by the Financial Conduct Authority ('FCA'). It is entered into the FCA's register and with registration number 409119. The registered office is 71 Kingsway,London, WC2B 6ST.
Shareholder Rights Directive (SRDII) On 31st May 2019 the FCA issued their Policy Statement 19/13 (PS19/13). This made changes to the FCA Handbook to implement the requirements of the amended Shareholder Rights Directive established by the European Union. The changes to the Handbook came into force on 10th June 2019 and introduced requirements for asset managers and insurers to publish details of their engagementpolicy.
We are pleased to announce our Engagement Policy, a copy of which canbe found here
.
2021 SV Health Investors LLPSite by Ether
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0